KIRYAT ONO, Israel & NEW YORK--(BUSINESS WIRE)--GammaCan International, Inc. (OTC BB: GCAN), a developer of immunotherapies for the treatment of cancer and other diseases, today announced that Patrick Schnegelsberg, Chief Executive Officer, is scheduled to present VitiGam, GammaCan's second generation product under development for the treatment of melanoma, to the investor, biotechnology and pharma community at the BioPartnering Europe Conference.
